Nivolumab and Ipilimumab

DRUG7 trials

Conditions

Carcinoma, Squamous Cell of Head and NeckCervix CancerGastric and Esophagogastric Junction AdenocarcinomaHBVHCVHIVLong COVIDMalignant Pleural Mesothelioma

Early Phase 1

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

TerminatedNCT03526185

Yale UniversityMetastatic Melanoma

Start: 2018-02-06End: 2020-12-01Updated: 2022-07-25

Phase 2

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

CompletedNCT03048474

The Netherlands Cancer InstituteMalignant Pleural Mesothelioma

Start: 2016-09-30End: 2019-12-31Updated: 2021-01-20

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Active, not recruitingNCT03443856

European Organisation for Research and Treatment of Cancer - EORTCGastric and Esophagogastric Junction Adenocarcinoma

Start: 2019-07-17End: 2026-06-30Updated: 2024-01-05

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

CompletedNCT03620123

AIO-Studien-gGmbHCarcinoma, Squamous Cell of Head and Neck, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Start: 2018-07-16End: 2022-06-19Updated: 2022-11-18

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Not yet recruitingNCT05597800

Universita di VeronaHBV, HCV, HIV +2

Start: 2023-02-01End: 2027-03-30Target: 105Updated: 2022-10-28

Phase 3

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

NCT04741438

Centre Leon BerardSarcoma

Start: 2021-03-30End: 2025-08-31Target: 96Updated: 2023-08-30

Unknown Phase

COL Immunotherapy Before Radiochimio + Ipilimumab

CompletedNCT04256213

ARCAGY/ GINECO GROUPCervix Cancer

Start: 2020-07-02End: 2024-08-04Updated: 2024-12-12

2026-01-05

Serum and tumor immune cell distribution as predictor of response to immune checkpoint blockade in solid tumors.

Journal of Clinical Oncology2025-05-28

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

Journal of Clinical Oncology2023-06-0112 citations

Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy

Journal for ImmunoTherapy of Cancer2023-06-016 citations

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study.

Journal of Clinical Oncology2021-05-208 citations

Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.

2020-11-0736 citations

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.

Journal of Clinical Oncology2020-02-018 citations

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Frontiers in Oncology2020-01-2993 citations

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

2019-01-16167 citations

Apollo (University of Cambridge)2019-01-01